Shasqi

🎉 Big news! We're thrilled to announce 6 presentations across two leading scientific conferences next week.    World ADC Event Series (San Diego):  👉 Two speaker sessions, featuring our CEO & Founder, José M. Mejía Oneto, and VP of Research Travis Biechele discussing approaches to overcome off-target toxicities associated with ADCs and sharing data from Shasqi’s novel Click Activated Protodrugs Against Cancer (CAPAC®) technology.  👉 Two posters sharing more details on CAPAC and data from our pipeline assets.  39th Annual Society for Immunotherapy of Cancer (SITC) Meeting:  👉 Two groundbreaking posters including first-in-human data from our Phase 1/2a sarcoma trial and exciting preclinical results demonstrating immune activation associated with MMAE administration via CAPAC.    We’re excited to continue existing conversations and start new ones around partnering our CAPAC pre-targeting technology. Interested? Reach out to Mukul Agarwal, drop a comment below or stop by at either conference!    Details 👇 https://lnkd.in/gkh8RAw9   #WorldADC #SITC2024 #SITC24 #biotech #innovation

Join us at #SITC2024 today! We're presenting two exciting posters showcasing our pre-targeting approach with click chemistry-enabled therapeutics:    🔬 Poster 624: 'Doxorubicin-based click chemistry therapeutic activates potent cytotoxic immune responses in advanced sarcoma patients in a Phase 1/2a clinical trial' 🔬 Poster 1278: 'Attenuated MMAE therapeutic activated by click chemistry at the tumor evokes potent immune responses'    📅 Saturday, November 9th  ⏰ 9:00 AM    #Cancer #research #biotech #innovation 

✨ In case you missed it, sharing our two latest posters from #WorldADC.    📊 'Pre-targeting with in vivo Click Chemistry Enables Preferential Drug Exposure in Tumors versus Normal Tissues' https://lnkd.in/gAfWM-Ct   📈 'CEACAM5 is an Ideal Target for Click Chemistry Enabled Pre-Targeting' https://lnkd.in/gGfHC-9k    Check out this timelapse of bringing these findings to life in one of our posters! From initial data selection to final design, each poster represents countless hours of data analysis, writing, design, and re-design. Nothing beats seeing the final product displayed at the conference!   Thank you to our incredible scientific team for their relentless pursuit of innovation in targeted therapeutics.   #drugdevelopment #biotech #innovation #BehindTheScenes"

Thank you to everyone who joined our presentation at #WorldADC today. Bet you were expecting José M. Mejía Oneto, our CEO & Founder? He’s been having so many great conversations, his voice gave out! Thankfully Travis Biechele jumped to the rescue. 💪 👉 𝗞𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆 𝗳𝗿𝗼𝗺 𝘁𝗼𝗱𝗮𝘆’𝘀 𝘀𝗲𝘀𝘀𝗶𝗼𝗻: In-vivo click chemistry is unlocking the potential of pre-targeting for both ADCs and radiopharmaceuticals, limiting off-target toxicities and increasing the therapeutic index of targeted therapies. Grateful for the engaging discussion and thoughtful questions from the audience. Let's keep pushing the boundaries of what's possible with targeted therapies. 🔬 #clickchemistry #ADC #innovation #biotech

Today at #WorldADC: Join our CEO & Founder, José M. Mejía Oneto, as he presents data from our novel CAPAC technology, a pre-targeting approach that uses in-vivo click chemistry to activate payloads at the tumor.  Come learn why this approach is a solution to overcoming off-target toxicities seen with ADCs. 🔬 Session: 'Click Chemistry Enabled Pre-targeting as a Solution to Target-independent ADC Toxicities'   📍 Discovery Chemistry Track  ⏰ 12:45pm PST #biotech #innovation #drugdevelopment #ADCs

Ready when you are! Come find Jesse McFarland and Michael Zakharian, they are excited to talk all things pre-targeting. Want to catch up with José or Travis? They'll be there too! 👉 Poster number 76 "Pre-targeting with in vivo Click Chemistry Enables Preferential Drug Exposure in Tumors versus Normal Tissues" 👉 Poster number 77 "CEACAM5 is an Ideal Target for Click Chemistry Enabled Pre-Targeting" #WorldADC #ADCs #biotech #innovation World ADC Event Series Hanson Wade Group

We’ve officially kicked off the main conference days at the 15th World ADC San Diego! Today’s panel session, “Moving the Needle Forward in 2025 & Beyond,” featured industry leaders from Pfizer, Johnson & Johnson, AstraZeneca, Ipsen, and Iksuda Therapeutics. The panel was moderated by Jeffrey Settleman #WorldADCSanDiego #ADC #biopharma #drugdiscovery #innovation

At #WorldADC San Diego and want to learn more about our Click Activated Protodrugs Against Cancer platform and how this pre-targeting approach can overcome dose limiting off-target toxicities associated with ADCs?    Look no further than today’s poster session where we’ll be presenting two posters.     Discover how our pre-targeting approach achieves increased tumor-targeted drug exposure while sparing healthy tissues, creating a greater therapeutic index. You can also learn why CEACAM5 is an ideal target for our technology.    Come meet our team, including José M. Mejía Oneto, Travis Biechele, Jesse McFarland, Mukul Agarwal, and Michael Zakharian and explore the future of targeted therapeutics.     #clickchemistry #adc #drugdevelopment #biotech #innovation #research

Thank you to everyone who attended Travis’ session at #WorldADC this morning! We're excited to have shared our thoughts on how pre-targeting with our CAPAC platform can limit off-target toxicities and improve patient benefit.    We look forward to more great discussions throughout the week - catch our poster session tomorrow evening! 🔬 2 Poster Presentations with Jesse McFarland and Michael Zakharian: Tuesday, Nov 5 - 6:30pm PST 📅 Shasqi CEO José M. Mejía Oneto speaking session: Wednesday, Nov 6 - 12:45pm PST    #biotech #research #innovation #adc

The Shasqi team have arrived in San Diego! Mukul, Travis, José, Michael, and Jesse are excited to join colleagues in the targeted therapy space over the next few days. Come find us to learn more about our technology👇 📅 Speaker Session: Wednesday, Nov 6 - 12:45pm PST  🔬 Poster Presentations: Tuesday, Nov 5 - 6:30pm PST #WorldADC #ADCs #biotech